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Abstract
Heat-stable enterotoxin (STa) stimulates intestinal Cl3 secretion by activating guanylate cyclase C (GCC) to increase
intracellular cyclic GMP (cGMP). In the colon, cGMP action could involve protein kinase (PK) G-II or PKA pathways,
depending on the segment and species. In the human colon, both PKG and PKA pathways have been implicated, and,
therefore, the present study examined the mechanism of cGMP-mediated Cl3 transport in primary cultures of human distal
colonocytes and in T84, the colonic cell line. Both cell preparations express mRNA for CFTR, Na-K-2Cl3 cotransporter
(NKCC1), GCC and PKG-II as detected by RT-PCR. The effects of STa and the PKG-specific cGMP analogues, 8Br-
cGMP and 8pCPT-cGMP, on Cl3 transport were measured using a halide-sensitive probe. In primary human colonocytes
and T84 cells, STa, the cGMP analogues and the cAMP-dependent secretagogue, prostaglandin E1 (PGE1), enhanced Cl3
transport. The effects of 8Br-cGMP and 8pCPT-cGMP suggested the involvement of PKG, and this was explored further in
T84 cells. The effects of 8pCPT-cGMP were dose-dependent and sensitive to the PKG inhibitor, H8 (70 WM), but H8 had no
effect on PGE1-induced Cl3 secretion. In contrast, a PKA inhibitor, H7 (50 WM), blocked PGE1-mediated but not 8pCPT-
cGMP-induced Cl3 transport. 8pCPT-cGMP enhanced phosphorylation of the PKG-specific substrate, 2A3, by T84
membranes in vitro. This phosphorylation was inhibited by H8. These results strongly suggest that cGMP activates Cl3
transport through a PKG-II pathway in primary cells and in the T84 cell line of the human colon. ß 2000 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Heat-stable enterotoxins (STa) elaborated by
pathogenic bacteria cause secretory diarrhea [1].
The ¢rst step in STa-mediated diarrhea is the activa-
tion of apical membrane-located guanylyl cyclase re-
ceptor C (GCC) leading to an increase in intracellu-
lar cyclic GMP (cGMP) [2]. The peptides guanylin
and uroguanylin [3,4] have been identi¢ed as the en-
dogenous ligands for GCC. Their localization, in-
cluding in the intestine, suggests they play a role in
intestinal £uid homeostasis [5,6]. The increase in in-
tracellular cGMP provokes net £uid loss primarily
by inhibiting sodium and water absorption and pro-
moting Cl3 secretion [1]. Chloride secretion is
achieved by the concerted action of Cl3 channels,
such as the cystic ¢brosis transmembrane conduc-
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tance regulator (CFTR) located in the apical mem-
brane, the Na-K-2Cl3 (NKCC1) cotransporter,
K channels and the Na/K-ATPase located on
the basolateral membrane of epithelial cells [7]. Acti-
vation of CFTR and/or NKCC1 and/or K channels
can lead to net Cl3 secretion [7].
In a variety of tissues, cGMP acts by stimulating
cGMP-speci¢c protein kinases (PKGs), of which
there are at least two major classes, PKG-I and
PKG-II. At su⁄ciently high concentrations, cGMP
can also act on cAMP-dependent protein kinases
(PKAs) [8]. However analogues of cGMP such as
8Br-cGMP and 8pCPT-cGMP cannot readily acti-
vate PKA [9]. While cGMP appears to act largely
via PKG-II in the small intestine [9], there is evidence
to suggest that cGMP utilizes multiple routes in the
colon. For example, there are segmental di¡erences
in the rat and rabbit colon where cGMP mediates its
e¡ect through PKG-II in the proximal segment,
while the distal segment lacks PKG-II [10,11]. Fur-
thermore, there are species di¡erences in the distal
colon. While the rabbit is totally non-responsive to
STa and cGMP [11,12], the rat distal colon secretes
Cl3 in response to STa and cGMP but appears to do
so by inhibiting a phosphodiesterase (PDE) [13],
which in turn increases cAMP levels and thereby
activation of PKA.
The evidence in the human colon is far from re-
solved. Studies from this laboratory in primary cul-
tures of human colonic epithelial cells (colonocytes),
using the PKG-speci¢c analogue 8Br-cGMP,
strongly suggest that PKG-II is operative in the
transverse colon [14] and may be present in the distal
colon [15]. In contrast, studies on the human colon
carcinoma cell line, T84, reveal variable results.
Some reports indicate that cGMP elicits its e¡ects
by cross-activating PKA [10,16,17], whereas another
study suggests involvement of membrane-bound
PKG [18].
Our laboratory has developed a method to mea-
sure Cl3 transport in small samples (9 2U104 cells),
using the halide-sensitive £uorescent probe 6-meth-
oxy-quinolyl-acetoethyl-ester (MQAE). This has
proven to be very e¡ective in studying the regulation
of Cl3 transport in human biopsy samples [12,14,19].
Utilizing this technique, we investigated if cGMP
could stimulate Cl3 transport in human distal colo-
nocytes and in T84 cells and if this process is medi-
ated by PKA or PKG-II pathway. Using reverse
transcription-polymerase chain reaction (RT-PCR),
we detected the expression of genes required for the
manifestation of cGMP-mediated Cl3 transport, viz.
CFTR, NKCC1, GCC and PKG-II. Further, we
demonstrate that a PKG-II pathway can account
for cGMP-mediated Cl3 transport in primary colo-
nocytes and in T84 cells.
2. Materials and methods
2.1. Materials
DMEM/F-12, Ham’s F-12, fetal bovine serum
(FBS), trypsin EDTA, Trizol and reagents for RT-
PCR were obtained from Life-Technologies Inc.
(Rockville, MD, USA). Collagenase, pronase, dithio-
threitol (DTT), insulin, glutamate, hydrocortisone,
selenium, sodium butyrate, antibiotics, Walsh inhib-
itor, H7 and H8 were procured from Sigma Chem-
icals (St. Louis, MO, USA). PKG substrate peptide,
2A3 (RRKVSKQE, s 95% purity), was custom-syn-
thesized by Alpha Diagnostics International (San
Antonio, TX, USA). MQAE was purchased from
Molecular Probes (Eugene, OR, USA). All other re-
agents were of analytical grade.
2.2. Human colonocyte isolation and culture
Human colonic biopsies were obtained from indi-
viduals undergoing colonoscopy using standard
pinch biopsy techniques as described previously
[15]. These studies were approved by the Institutional
Review Board at the University of Illinois at Chica-
go. Ten biopsies (100^120 mg tissue) were procured
from each patient after obtaining informed consent.
To ensure uniformity of tissue between donors, sam-
ples were taken from the sigmoid colon within 5^15
cm from the anal verge. For the transport studies,
human distal colonic epithelial cells were isolated as
described previously [14]. In brief, the colonic biop-
sies were transported on ice in oxygenated lactated
Ringers containing 5 mM dextrose and antibiotics (in
Wg/ml: ampicillin 25, penicillin 120, streptomycin 270
and amphotericin B 1.25). The biopsies were care-
fully dissected to remove any adherent submucosal
tissue and underlying muscle. The samples were di-
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gested with 0.1% pronase and 0.03% collagenase for
90 min at 37‡C in the presence of 5 mM DTT. The
cells were ¢ltered to remove residual tissue and seri-
ally centrifuged to enrich for crypt cells [14]. Colo-
nocytes were cultured overnight at 2U104 cells/ml in
tissue culture media (Ham’s F-12 nutrient mix) sup-
plemented with 20% FBS, insulin (0.5 U/ml), L-glu-
tamine (4 mM), hydrocortisone (1 WM), selenium
(10.5 mM), sodium butyrate (0.5 mM) and antibiot-
ics. Isolated, non-attached colonocytes following 18 h
culture were used for the transport studies.
2.3. Cell culture
T84 cells were grown in DMEM/F-12 media con-
taining 10% FBS and a cocktail of antibiotics con-
taining ampicillin (25 Wg/ml), streptomycin (270 Wg/
ml) and amphotericin B (1.25 Wg/ml). To parallel the
conditions used for primary cultures, con£uent cells
were detached by incubating with trypsin at 37‡C for
5 min and suspended cells were used for chloride
transport studies.
2.4. Chloride transport
Chloride transport was measured using the halide-
sensitive £uorescence probe MQAE as described ear-
lier [14]. Suspended cells were loaded with the
MQAE (5 mM) in bu¡er A containing (in mM)
110 NaCl, 1 MgCl2, 1 CaCl2, 5 dextrose, 50 mannitol
and 1 KCl, for 90 min at 4‡C. The cells were then
suspended in a chloride-free bu¡er B containing (in
mM) 110 sodium isethionate, 1 MgSO4, 5 dextrose,
50 mannitol, 1 K2SO4 and 1 CaSO4. Fluorescence
was measured in a PTI spectro£uorometer (Prince-
ton, NJ, USA) at an excitation wavelength of 355
nM and an emission wavelength of 460 nM. Cells
were incubated þ stimulants and þ inhibitors (diphe-
nylamine 2-carboxylate, 50 WM; and furosemide, 10
WM) for 5 min and the change in £uorescence after
the addition of 5 mM NaCl was measured. Back-
ground £uorescence was obtained by adding 150
mM KSCN. Cl3 in£ux was calculated using the for-
mula JCl3 = (F0/KClF2)(dF/dt), where JCl is the rate of
Cl3 in£ux (mM/s), dF/dt is the slope of the initial
rate of change of £uorescence upon addition of Cl3,
KCl3 is the Stern^Volmer constant for quenching in-
tracellular MQAE by Cl3, and F0 and F are absolute
£uorescence in the absence and presence of Cl3, re-
spectively. The background £uorescence was de-
ducted from both F and F0.
2.5. Determination of KCl3
Intracellular anions and non-physiological anions
such as thiocyanate quench MQAE £uorescence to
varying extents [20]. To account for this, the Stern^
Volmer constant, KCl3 , has to be determined for each
cell type. KCl3 for T84 cells and human colonocytes
was measured by quenching MQAE £uorescence
with the addition of increasing concentrations of
Cl3. Stern^Volmer constant (KCl3) is the slope of
the equation F0/F = 1+KCl3 [Cl3], where [Cl3] is the
Cl3 concentration. The KCl3 values for T84 and hu-
man colonocytes used for these studies were 96 M31
and 98 M31, respectively.
2.6. RNA isolation and RT-PCR
Total RNA was isolated by a one step extraction
method using the Trizol isolation kit (Life-Technol-
ogies, Rockville, MD, USA). The quality of RNA
was assessed by fractionating on 1% agarose gel
and observing the presence of the typical 18S and
28S rRNA under UV-light.
RT-PCR was carried out as described earlier
[14,21]. In brief, total RNA (10 Wg) was reverse-tran-
scribed to ¢rst strand cDNA with 200 U of Moloney
murine leukemia virus reverse transcriptase in the
presence of 0.5 mM dNTPs and 25 Wg/ml oligo(dT)
in a total volume of 20 Wl for 60 min at 40‡C. After
the reaction, samples were boiled at 95‡C for 5 min
and transferred to 320‡C. PCR was performed in a
total volume of 50 Wl with 5 Wl reverse-transcribed
product, 2.5 U Taq-polymerase, 50 WM dNTPs, 0.6
WM primers in 1UPCR bu¡er. Ampli¢cation was
performed using one cycle at 95‡C for 3 min fol-
lowed by 25^30 cycles at 95‡C for 30 s, 55‡C for
30 s and 72‡C for 30 s and the ¢nal extension at
72‡C for 5 min (Hybaid, UK). The PCR products
were analyzed in 2% agarose gel, stained with ethid-
ium bromide and visualized under UV. Primers used
in PCR were designed from the coding region of
various cDNAs using the software Lasergene
(DNASTAR, Madison, WI, USA). The primers
used in this study are provided in Table 1.
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2.7. Measurement of intracellular cGMP
T84 cells, grown to 95^100% con£uency in 60 mm
dishes, were used for cGMP measurement. The cells
were pre-incubated with 1 mM IBMX in serum-free
media for 30 min at 37‡C followed by stimulation
with STa (100 nM) for 15 min at 37‡C. The cells
were lysed with sodium acetate, boiled for 10 min
and centrifuged for 5 min at 14 000Ug. The resulting
supernatant was acetylated and assayed for cGMP
using the Titerzyme cGMP EIA kit (PE Biosystems,
CA, USA). Protein was estimated by the BCA meth-
od [22].
2.8. Preparation of membranes and determination of
PK activity
Con£uent T84 cells in 100 mm dishes were washed
in ice-cold phosphate-bu¡ered saline and scraped in
lysis bu¡er (20 mM Tris^HCl, pH 7.4, 5 mM L-mer-
captoethanol, 2.5 mM EDTA, 1 mM PMSF, 10 Wg/
ml leupeptin, 5 Wg/ml aprotinin and 5 Wg/ml pepsta-
tin A). The cells were brie£y sonicated (two pulses of
5 s, peak to peak amplitude 20 Wm). Crude mem-
brane fraction was prepared by centrifugation at
20 000Ug for 15 min. Membrane was suspended in
lysis bu¡er. PKG-II activity in the membrane was
determined as described by Vaandrager et al. [23].
In brief, the membrane samples (40 Wg) were pre-
incubated at 30‡C for 2 min in 35 Wl of 20 mM
Tris^HCl, pH 7.4, 10 mM L-mercaptoethanol, 0.1
mM IBMX, 200 nM PKA inhibitor (Walsh inhibi-
tor), 0.1 mg/ml PKG-speci¢c substrate 2A3
(RRKVSKQE) þ 8pCPT-cGMP (0.1 mM) and
þ H8 (10 WM). Kinase activity measurement was ini-
tiated by adding 5 Wl of Mg-ATP mix (0.3 mM ATP,
10 mM MgCl2 and 1 WCi of [Q-32P]ATP) for 10 min
at 30‡C. The reaction was terminated by transferring
the samples to ice followed by addition of 5 Wl of 0.5
mM EDTA. The samples were centrifuged for 10
min at 20 000Ug. Pellet was suspended in Laemmli
bu¡er for determination of autophosphorylation of
PKG-II, and 15 Wl of the supernatant was spotted on
P-81 chromatography paper (Whatman, Kent, UK).
The chromatography paper was air-dried, washed
three times in 1% phosphoric acid, washed once in
water and dried fast in incubator. The amount of 32P
incorporated was quantitated with PhosphorImager
(Molecular Dynamics, CA, USA).
2.9. Statistics
Statistical signi¢cance was calculated using AN-
OVA followed by Fisher’s LSD (protected t) test.
Values of P6 0.05 were considered signi¢cant. In
experiments, n values were v3 and in each experi-
ment, the measurements were done in triplicate.
3. Results
3.1. Expression of cGMP-mediated signaling proteins
in T84 cells
To demonstrate that primary human colonocytes
possess the transcripts for the transport proteins,
CFTR and NKCC1, and for the cGMP signaling
cascade proteins, GCC and PKG-II, RT-PCR was
Table 1
Primers used for PCR
Gene/locus of product Sense Anti-sense Size (bp)
Human Na/K/2Cl3,
secretory/C-terminal region
5P-GAG AGC GAT GGC TAC TTT GC-3P 5P-TAC CAT TCT GGA GGG CTG TC-3P 468
Rabbit CFTR/¢rst trans-
membrane domain




5P-ATA CAA TCC AGA GAC TAC GAC-3P 5P-GCT CTT TTT CCT CTG CTG TTT-3P 660
Human PKG-II/N-terminal
region
5P-TGG ACA CTC TGG GAA CCT CA-3P 5P-CCT TTG CTC CCC TCC TGC T-3P 323
Human PKG-II/cytoplasmic
region
5P-GTG GGT TCG GAA GAG TTG AGC-3P 5P-TCC CAG TGA CCA GAA ATC C-3P 527
Human GAPDH 5P-ATG GCA CCG TCA AGC CTG AGA-3P 5P-GGC ATG GAC TGT GGT CAT GAG-3P 371
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performed using speci¢c primers (Table 1). We took
advantage of two characteristics of CFTR to demon-
strate speci¢city of the primers: ¢rst, it is highly con-
served between rabbit and human; second, rabbit
heart CFTR lacks exon 5. We therefore designed
primers to amplify a region spanning exon 5. This
is expected to yield a 440 bp ampli¢ed product in
rabbit heart and a 530 bp product in other tissues.
RNA isolated from biopsy of human distal colon (C)
and T84 cells ampli¢ed a message of 530 bp whereas
a 440 bp product was ampli¢ed in rabbit heart, con-
¢rming the speci¢city of the primer (Fig. 1A). In
rabbit brain, CFTR primers failed to amplify a spe-
ci¢c product, which served as a negative control.
Primers for NKCC1, based on the published human
cDNA sequence, ampli¢ed an expected 468 bp prod-
uct in T84 and the human distal colonic cells (Fig.
1B).
Primers, based on the cytoplasmic domain of hu-
man GCC, ampli¢ed an expected product of 660 bp
in both human distal colonocytes and T84 cells (Fig.
2C). Rabbit heart and brain are known to express
the receptors, GCA and GCB, for natriuretic pep-
tides. However, GCA and GCB bear little homology
to GCC in their cytoplasmic domain [24]. The GCC
primers failed to amplify any product in rabbit heart
and brain, but ampli¢ed a product in rabbit colon.
Thus the lack of any product in the heart and brain
con¢rms the speci¢city of the selected primers. This
demonstration of GCC in the distal colon con¢rms
the earlier functional studies with STa in colon
[15,25,26].
To detect PKG-II transcript, we designed two sets
of unique primers. The PKG-II sequence di¡ers from
that of its closest isoform, PKG-I, in two regions:
the N-terminal region and the hinge region between
the regulatory and the catalytic domains [9,27]. We
designed one set of primers to amplify a 323 bp
region at the 5P end of the gene and another to am-
plify a 527 bp product in the hinge region. Using
both sets of primers, transcripts for PKG-II were
observed in human distal colon as well as in T84
cells (Fig. 2A,B). Rabbit brain, a tissue known to
contain PKG-II, but not rabbit heart showed a pos-
itive reaction product establishing speci¢city of the
primer (Fig. 2A). The data from T84 cells were
somewhat surprising, since earlier reports had failed
to detect PKG-II in T84 cells [10]. Therefore, to con-
¢rm that the PCR product ampli¢ed in T84 cells was
indeed PKG-II, the 323 bp product was sequenced
and found to be 100% identical to the published
human cDNA sequence for PKG-II (data not
shown). In all studies, the quality of RNA was con-
¢rmed by amplifying the house-keeping gene
GAPDH (Fig. 2D).
3.2. Regulation of Cl3 transport by cGMP agents
We had previously demonstrated that STa caused
an increase in intracellular cGMP in primary human
Fig. 1. Expression of CFTR and NKCC1 in T84 cells and human distal colonic mucosa. Total RNA (10 Wg) isolated from T84 cells
(T84) and human distal colonic mucosa (C) were subjected to reverse transcription followed by ampli¢cation of mRNA by PCR using
speci¢c primers for CFTR and NKCC1. Primers used for CFTR ampli¢ed a product of 530 bp corresponding to the ¢rst transmem-
brane domain of the rabbit CFTR, and the NKCC1 primer was selected to amplify 468 bp sequence in the carboxy-terminal domain
of human NKCC1. Key: B, brain; H, heart; C, human distal colon; T84, T84 cells.
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colonocytes [15]. To establish that STa increased
cGMP in T84 cells as well, we measured [cGMP]i
in T84 cells treated with 100 nM STa for 15 min.
As reported by others [16,28], STa caused a robust
296-fold increase in cGMP content in T84 cells
(fmol/Wg protein, control: 3.1 þ 2.4 vs. +STa:
918.6 þ 28.4; n = 3 in duplicate).
We next explored if PKG has a functional role in
human colonocytes and T84 cells. As previously
shown [15], furosemide and DPC inhibited basal,
STa and 8Br-cGMP-stimulated Cl3 transport (data
not shown). In the presence of inhibitors, the val-
ues þ secretagogues were the same, and therefore all
data are reported as inhibitor-sensitive Cl3 trans-
port.
To ensure that the cells could exhibit Cl3 trans-
port, prostaglandin E1 (PGE1), a well known cAMP-
dependent stimulator of Cl3 secretion [20], was used
as a control. In primary human distal colonocytes,
STa (25 nM) caused a signi¢cant increase in inhib-
itor-sensitive Cl3 transport (+STa: 0.35 þ 0.08 vs.
basal: 0.14 þ 0.04 mM/s, Fig. 3A) as did PGE1 (1
WM: 0.33 þ 0.05 mM/s). To test if the e¡ect of STa
is through PKA or PKG, we used 8Br-cGMP and
8pCPT-cGMP which can only activate PKGs [29].
8Br-cGMP (100 WM) stimulated Cl3 in£ux 2.9-fold
(0.41 þ 0.08 mM/s), whereas 8pCPT-cGMP (100 WM)
stimulated Cl3 in£ux 3.9-fold (0.55 þ 0.1 mM/s).
Similarly, in T84 cells, as shown in Fig. 3B, STa
caused a 1.8-fold (+STa: 0.34 þ 0.03 vs. basal:
0.19 þ 0.04 mM/s) increase in inhibitor-sensitive Cl3
in£ux and PGE1 caused a 1.7-fold increase
(0.32 þ 0.03 mM/s). Interestingly, 8Br-cGMP
(0.38 þ 0.05 mM/s) and 8pCPT-cGMP (0.33 þ 0.05
mM/s) signi¢cantly caused a W2-fold stimulation
of Cl3 in£ux in T84 cells (Fig. 3B). In a separate
series of experiments, we examined the combined ef-
fects of cAMP- and cGMP-dependent secretagogues.
The values of a representative experiment performed
in triplicate are as follows: (+PGE1 : 0.37 þ 0.01;
+8pCPT-cGMP: 0.55 þ 0.07; STa: 0.50 þ 0.02;
PGE1+8pCPT-cGMP: 0.53 þ 0.04; PGE1+STa:
Fig. 2. Detection of PKG-II and GCC transcripts in T84 cells and human distal colonic mucosa by RT-PCR. PKG-II primer ampli-
¢ed a 323 bp sequence in the amino-terminal domain of PKG-II (A) or a 527 bp product in the hinge region between the cGMP
binding domain and the catalytic domain of human PKG-II (B). GCC primer was selected to amplify a 660 bp sequence in the cyto-
plasmic domain of human GCC (C). GAPDH primers were used to amplify the house-keeping gene (D). Key: B, brain; H, heart; C,
primary human distal colon; RC, rabbit colon; T84, T84 cells.
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0.47 þ 0.03; vs. basal: 0.22 þ 0.03 mM/s). The trans-
port rates elicited by the cGMP-dependent secreta-
gogues could not be further augmented by the com-
bined addition of PGE1.
Further studies to validate the role of PKG were
performed in the more readily available T84 cells.
We examined the e¡ects of varied concentrations of
8pCPT-cGMP. As can be seen in Fig. 4, this cGMP
analogue caused a dose-dependent increase in Cl3
transport in T84 cells, with a signi¢cant increase at
1 WM and a maximal e¡ect at 200 WM 8pCPT-
cGMP.
3.3. E¡ect of PK inhibitors on Cl3 transport in
T84 cells
To examine which kinase(s) are involved in
cGMP-mediated Cl3 transport in T84 cells, we
took advantage of speci¢c inhibitors for PK. As
seen in Fig. 5A, pretreating the cells with H7 (50
WM), the PKA-speci¢c inhibitor, did not alter basal
Cl3 in£ux (untreated: 0.16 þ 0.05 vs. H7-treated:
0.18 þ 0.02 mM/s). However, H7 inhibited PGE1-in-
duced Cl3 in£ux (PGE1 : 0.40 þ 0.05 vs. PGE1+H7:
0.19 þ 0.01 mM/s, Fig. 5A). On the other hand, H7
did not alter 8pCPT-cGMP-mediated Cl3 in£ux
(0.46 þ 0.06 vs. 0.48 þ 0.05 mM/s, respectively, Fig.
5A) but it attenuated STa-stimulated Cl3 secretion
(0.52 þ 0.05 vs. 0.37 þ 0.04 mM/s, respectively, Fig.
5A). However, H8, a PKG-II-speci¢c inhibitor, abol-
ished 8pCPT-cGMP-stimulated Cl3 secretion
(0.57 þ 0.14 vs. 0.19 þ 0.02 mM/s in the absence and
presence of H8, respectively, Fig. 5B). While H8 had
no e¡ect on PGE1-mediated Cl3 in£ux (0.49 þ 0.11
vs. 0.49 þ 0.04 mM/s, respectively, Fig. 5B), it signi¢-
cantly reduced STa-stimulated Cl3 secretion
(0.58 þ 0.15 vs. 0.32 þ 0.06 mM/s, respectively, Fig.
5B).
Fig. 3. E¡ect of agents that increase cGMP and cAMP on Cl3
in£ux in primary human distal colonocytes (A) and T84 cells
(B). Cells were loaded with MQAE, Cl3-depleted and treated
with agents with or without inhibitors (diphenylamine 2-carbox-
ylate, 50 WM and furosemide, 10 WM) for 5 min at room tem-
perature. Initial £uorescence was taken followed by the addition
of NaCl (5 mM). The rate of change of £uorescence after addi-
tion of NaCl was monitored. At the end of the experiment,
KSCN (150 mM) was added to quench MQAE £uorescence
completely. Cl3 in£ux was calculated using the formula
JCl3 = F0/KCl3F2WdF/dt, where dF/dt is the rate of change of
£uorescence, KCl3 is the Stern^Volmer constant, F0 is the di¡er-
ence in £uorescence units in the absence of Cl3 and in the pres-
ence of KSCN, and F is the di¡erence in £uorescence units in
the presence of Cl3 and that in presence of KSCN. Data are
expressed as inhibitor-sensitive Cl3 in£ux in mM/s, after sub-
tracting the Cl3 in£ux in the presence of inhibitors. Values are
mean þ S.E.M., n = 4, *P6 0.05; **P6 0.01, ANOVA.
Fig. 4. Dose response of 8pCPT-cGMP to stimulate Cl3 trans-
port in T84 cells. Cl3 in£ux in T84 cells was measured as de-
scribed in Section 2 and the legend of Fig. 3 with increasing
doses of 8pCPT-cGMP. The data represent the inhibitor-sensi-
tive Cl3 transport (net Cl3 transport obtained after subtracting
the Cl3 in£ux in presence of DPC and furosemide). Values are
mean þ S.E.M., n = 3, *P6 0.01, ANOVA.
BBAMCR 14661 10-10-00
N.G. Selvaraj et al. / Biochimica et Biophysica Acta 1498 (2000) 32^4338
3.4. Determination of PKG-II activity in
T84 membranes
To con¢rm that the above observations are indeed
due to the presence of PKG-II protein, we assayed
for the presence and activity of the protein in T84
membrane preparations. Activity was measured us-
ing two assays: ¢rst, the ability of T84 membrane
proteins to phosphorylate the PKG-speci¢c peptide
substrate 2A3 (RRKVSKQE) þ 8pCPT-cGMP was
tested. Second, we took advantage of the fact that
PKG-II is autophosphorylated upon activation and
analyzed this by Western blotting and autoradiogra-
phy. Freshly isolated membranes (40 Wg) from T84
cells in the presence of the PKA-speci¢c Walsh in-
hibitor were incubated with 2A3 substrate þ 8pCPT-
cGMP (0.1 mM) þ H8 (10 WM). At the end of the
reaction, the substrate was separated from the mem-
branes and the enzyme-containing membrane frac-
tion saved for Western analyses. As shown in Fig.
6A, phosphorylation of 2A3 was increased 63% by
8pCPT-cGMP and reduced to baseline levels by H8.
To assess PKG-II autophosphorylation, the mem-
branes used in the kinase assay were resolved on
SDS^PAGE followed by Western blotting. This
blot was probed with PKG-II antibody (Fig. 6B)
and subjected to autoradiography. The antibody rec-
ognized a speci¢c 80 kDa band in the rat proximal
colon (lane 5) used as a positive control. Non-radio-
labeled T84 samples (lane 6), as well as those used in
the kinase assay (lanes 1^4), revealed an 80 kDa
band corresponding to PKG-II. In addition, a band
at 55 kDa (not shown), similar to that reported by
Markert et al. [30], was observed. The lower bands
are not seen in the rat samples although similar cock-
tails of protease inhibitors were used in the two
membrane preparations. PhosphorImager analysis
of the blot indicates that the cGMP analogue stimu-
lated autophosphorylation in T84 membranes. Quan-
titation of the 80 kDa band revealed the following
values relative to basal: +H8: 0.85; 8pCPT-cGMP:
2.6 and 8pCPT-cGMP+H8: 1.42. Taken together,
these results demonstrate the presence and activity
of PKG-II in human colonic T84 membranes.
4. Discussion
In the mammalian small and large intestine, STa
stimulates Cl3 secretion by binding to and activating
its membrane receptor, GCC, to increase intracellu-
lar cGMP [1,2]. While the signaling cascade in the
small intestine appears to follow the canonical path-
way of STaCcGMPCPKGCsubstrate, the picture
Fig. 5. E¡ect of PK inhibitors on Cl3 in£ux in T84 cells. T84 cells were loaded with MQAE for 90 min in ice in either the presence
or absence of H7 (50 WM) or H8 (70 WM), followed by transfer of the cells to Cl3-free bu¡er containing the inhibitors for 30 min.
The cells were incubated þ secretagogues and þ Cl3 transport inhibitors (DPC and furosemide) for 5 min and Cl3 £ux calculated as
indicated in Section 2. Data are expressed as inhibitor-sensitive Cl3 in£ux in mM/s, after subtracting the Cl3 in£ux in presence of in-
hibitors and is mean þ S.E.M., n = 4; each treatment carried out in triplicate. a, P6 0.01, ANOVA.
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in the colon is more varied and appears to depend on
the segment, species and type of cell preparation used
[2]. Evidence for this stems chie£y from transport
and biochemical measurements in a variety of pri-
mary tissue and cell line models. Thus, at least three
di¡erent signal transduction mechanisms have been
proposed to link cGMP signaling to Cl3 transport in
the mammalian colon: cGMP activation of PKG-II
[10] ; cGMP directly binding to and activating PKA
[16,17]; and cGMP inhibition of speci¢c PDEs lead-
ing to an increase in intracellular cAMP, which in
turn activates PKA [13]. In the rat, there is clear
evidence for STa acting via a PKG-II mechanism
in the proximal colon [10] and via PDE in the distal
colon [13]. In the human colon, using the PKG-spe-
ci¢c analogue, 8Br-cGMP, we had earlier suggested
that a PKG mechanism is operative in primary cul-
tures of distal colonic epithelial cells [15]. In the hu-
man colonic cell line, T84, Forte et al. demonstrated
that, while STa could stimulate intracellular cGMP
Fig. 6. Stimulation of PKG activity in T84 membrane by 8pCPT-cGMP. A: Phosphorylation of 2A3 substrate by T84 membrane pro-
teins was measured in presence or absence of 8pCPT-cGMP (0.1 mM) and H8 (10 WM) for 10 min at 30‡C as described in Section 2
in the presence of the PKA-speci¢c Walsh inhibitor. Values are mean þ S.E.M., n = 4; a, P6 0.01, compared to basal; b, P6 0.05,
compared to 8pCPT-cGMP, ANOVA. B: Autophosphorylation and Western analysis of T84 membranes. Membrane fractions of T84
cells, following in vitro phosphorylation, were suspended in Laemmli bu¡er and resolved by SDS^PAGE on 7.5% gel. Membrane
samples (40 Wg) not exposed to [32P]ATP from rat intestine and T84 cells were also included in the gel. The proteins were electrotrans-
ferred to nitrocellulose membrane and the blot probed with PKG-II antibody. PhosphorImager quantitation of the 80 kDa band in
the [32P]ATP samples is given below. RP, rat proximal colon; T84, T84 membrane.
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and Cl3 transport, 8Br-cGMP had no e¡ect and that
there was no biochemically detectable PKG activity
[16]. However, other studies in T84 cells suggested
that there was 8Br-cGMP-sensitive Cl3 current
[31]. Since both PKG [18] and PKA [10,16,17] path-
ways have been implicated in di¡erent studies of the
human colon, in the present study, we examined the
mechanism of cGMP-mediated Cl3 transport in pri-
mary cultures of human distal colonocytes and in the
colonic cell line, T84.
In epithelia, Cl3 secretion occurs by the concerted
action of the secretory isoform of the NKCC1 co-
transporter and Cl3 channels like CFTR [1]. We and
others have previously reported that intact human
colonic epithelia [15,26] or primary cultures of iso-
lated human colonocytes [14] exhibit Cl3 transport
and, through the use of speci¢c inhibitors, have dem-
onstrated that this transport involves NKCC as well
as CFTR [14,26]. Similar information for T84 cells is
well-documented [32]. We demonstrate here that
both cell preparations express mRNA for CFTR
and NKCC1. However, as reported earlier, adult
rabbit brain does not express CFTR [33]. In data
not shown, we were unable to detect any transcripts
for NKCC2, the ‘absorptive form’ of the cotrans-
porter in T84 cells.
The localization of the STa receptor, GCC, in the
colon, has been reported in a number of studies.
Thus, in rat colon, GCC mRNA was localized to
colonic crypts and surface epithelia [34]. A study of
125I-STa binding in mammalian colon, including hu-
man, demonstrated GCC binding to be greatest in
the proximal region [35]. The present study con¢rms
the presence of GCC transcripts and activity in T84
cells and of transcripts in primary cultures of distal
human colonocytes.
The major cGMP signaling mechanism in the
small intestine is via the PKG-II isoform. Using spe-
ci¢c primers for PKG-II and the highly sensitive RT-
PCR methodology, we demonstrate for the ¢rst time
that colonocytes isolated from the human distal co-
lon and T84 cells possess transcripts for PKG-II. The
presence of PKG-II transcript in T84 cells is novel
since this cell type was previously suggested not to
possess PKG [30]. Two sets of primers designed from
di¡erent regions ampli¢ed the expected size message
in T84 cells. The demonstration of PKG-II tran-
scripts in T84 cells was intriguing and led us to ex-
plore if PKG activity can be measured in these cells.
Both autophosphorylation and in vitro phosphoryla-
tion assays con¢rmed the presence of functional
PKG-II in T84 cells.
How does the presence of PKG enzymatic activity
relate to transport function? In terms of transport,
there are con£icting results in the literature regarding
the mechanism of cGMP action in T84 cells based on
studies with various cGMP analogues [10,16,18].
There is considerable promiscuity in the action of
cyclic nucleotides [8]. The analogues of cGMP have
been reported to have variable e¡ects on T84 cell Cl3
transport. Thus, 8Br-cGMP was either shown to
have no e¡ect [10,16,30] or to stimulate [31] short-
circuit current, a measure of Cl3 transport, in T84
cells. While Chao et al. have reported that 8pCPT-
cGMP increased Cl3 channel activity in T84 cells
[17], Vaandrager et al. indicate that this analogue
had no signi¢cant e¡ect on short-circuit current
[10]. The present study demonstrates that 8Br-
cGMP and 8pCPT-cGMP stimulate Cl3 transport
in primary human distal colonocytes. Equally impor-
tant, we demonstrate that both of these PKG-speci¢c
analogues increase Cl3 transport in T84 cells, sug-
gesting that a PKG mechanism is involved in STa
action. The e¡ects of combined addition of
PGE1+8pCPT-cGMP or PGE1+STa in T84 cells is
not di¡erent from the e¡ect obtained with either
8pCPT-cGMP or STa alone. We interpret this to
mean that the ability to stimulate the transport ma-
chinery is ¢nite. Thus 8pCPT-cGMP or STa maxi-
mally activate the transport machinery and activa-
tion of the cAMP cascade cannot further stimulate
the transporters. Similar non-additive e¡ects of these
two cascades acting via di¡erent kinases have been
reported in the rabbit ileum [36] and are well known
for the Ca2 and cAMP cascades in a variety of
epithelia.
The isoquinoline sulfonamides H7 and H8 have
been used as e¡ective tools in colonic tissue to block
PKA- and PKG-dependent pathways, respectively
[23,37]. Thus in our studies, H8 blocked 8pCPT-
cGMP-mediated Cl3 transport, while it had no e¡ect
on the PGE1-stimulated cAMP signaling pathway. In
contrast, H7 blocked PGE1-stimulated Cl3 trans-
port, but did not block the 8pCPT-cGMP e¡ect on
Cl3 transport. The e¡ect of STa in T84 cells is sig-
ni¢cantly inhibited by H8. It is of interest that in
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contrast to its lack of e¡ect on 8pCPT-cGMP action,
H7 also caused a small but signi¢cant inhibition of
STa-stimulated Cl3 transport. The e¡ects of H7 on
STa action are in keeping with earlier observations
[10,16,17] that STa-stimulated cGMP can activate
PKA in T84 cells. This is perhaps due to the tremen-
dous,W300-fold, stimulation of cGMP in these cells,
levels which are much greater than the 2^11-fold re-
ported in primary isolates of human colon [15,26].
Thus in our preparations of T84 cells, STa may be
acting by both PKG and PKA to stimulate Cl3
transport.
The variability in the STa signaling pathway of
T84 cells reported in this and other studies
[10,16,30] may be due to di¡erences in the T84 sub-
clones used in various laboratories. Indeed, a di¡er-
ence in the expression of PKG-II in cells in culture
has been reported [38]. Discrepant observations in an
extensively studied transformed cell line argue for
caution in extrapolating data and/or making general-
izations from such model systems. Collectively, our
results in T84 cells and primary human distal colo-
nocytes suggest that STa and other cGMP-dependent
activators utilize a PKG mechanism to modulate Cl3
transport. While, in T84 cells, STa increases cGMP
to high enough levels to activate PKA, it remains to
be determined if such concentrations of cGMP are
ever achieved in the intact human colon under any
physiological/pathological state.
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